UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): ~~February~~March 2624, 2026

Neurogene Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-36327	98-0542593
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

535 W 24th Street, 5th Floor

New York, NY 10011

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (877) 237-5020

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value

NGNE

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition

On ~~February~~March 2624, 2026, Neurogene Inc. (the “Company”) issued a press release announcing ~~that~~financial ~~NGN-401,~~results for the ~~Company's~~quarter ~~investigational~~and ~~gene~~year ~~therapy~~ended inDecember ~~late-stage~~31, ~~clinical~~2025. ~~development~~A ~~for~~copy of the ~~treatment~~press ofrelease ~~Rett~~announcing ~~syndrome,~~such ~~has~~results ~~received~~is ~~Breakthrough~~attached ~~Therapy~~as ~~Designation~~Exhibit ~~from~~99.1 ~~the~~to Uthis Current Report on Form 8-K.S. ~~Food~~Also ~~and~~on ~~Drug~~March ~~Administration~~24, 2026, the Company posted an updated corporate presentation on its website. A copy of the ~~press~~corporate ~~release~~presentation is ~~attached~~furnished as Exhibit 99.12 to this Current Report on Form 8-K.

The information in this Item 72.0102 and ~~Exhibit~~Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or ~~Exhibit~~Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.


Item 9.01			Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber						Description
99.1						Press Release dated ~~February~~March 2624, 2026
99.2						Corporate Presentation (March 2026)
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NEUROGENE INC.
Date: February 26, 2026	By:	/s/ Christine Mikail
Date: March 24, 2026	By:	/s/ Christine Mikail
		Name: Christine Mikail
		Title: President, Chief Financial Officer

Filing Compare · Neurogene Inc.